A recent peer-reviewed study published in The Lancet Regional Health – Europe estimates that the number of patients eligible for radioligand therapies (RLTs) in the EU-27 could increase from 10,700–13,200 in 2025 to 125,900–182,600 by 2035. To assess the implications for healthcare systems, the analysis also modeled treatment uptake scenarios in Germany, France, Italy, and Spain. The findings highlight the potential scale of demand over the next decade and provide insights for long-term planning of the infrastructure, workforce, and healthcare capacity needed to ensure access to RLTs.